Sutro Biopharma, INC

Sutro Biopharma, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and ratification of its independent auditor.

Sutro Biopharma announced improved full year 2025 financial results, significant pipeline advancements, and an extended cash runway into Q2 2028 following a recent capital raise.

Sutro Biopharma announced a public offering of 7.87 million common shares at $13.98 each, raising approximately $110 million to extend its cash runway into Q2 2028.

Sutro Biopharma, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, closing a previously disclosed listing matter.

Sutro Biopharma, Inc. will implement a 1-for-10 reverse stock split effective December 3, 2025, to regain Nasdaq compliance.

Sutro Biopharma announced its third quarter 2025 financial results, highlighted by FDA IND clearance for STRO-004 and an extended cash runway into mid-2027.

Sutro Biopharma reported a reduced net loss in Q3 2025, driven by strategic restructuring and a sharpened focus on its preclinical ADC pipeline, while addressing Nasdaq listing compliance.

Sutro Biopharma reported a reduced net loss and increased revenue driven by a strategic restructuring, deprioritizing STRO-002 and STRO-003 programs while focusing on preclinical assets STRO-004 and STRO-006, amidst a 50% workforce reduction and Nasdaq listing concerns.

Sutro Biopharma reports Q1 2025 results, details restructuring plan involving pipeline prioritization and workforce reduction.

Sutro Biopharma's Q3 2024 report reveals a net loss of $48.8 million, alongside updates on clinical trials and collaborations.

Sutro Biopharma's second quarter 2024 results show increased revenue driven by collaborations, alongside significant R&D spending and a net loss, while highlighting key clinical advancements.

Sutro Biopharma's first quarter 2024 results show increased revenue from collaborations, offset by higher R&D spending and a net loss, while also highlighting key clinical advancements and a new licensing agreement.

Sutro Biopharma reported a net loss of $191.1 million for 2025, driven by strategic restructuring and a refocused pipeline on novel ADC candidates STRO-004, STRO-006, and STRO-227.

Sutro Biopharma's 2024 10-K filing reveals a strategic shift towards prioritized pipeline programs and a significant workforce reduction to extend its cash runway.

Sutro Biopharma's 10-K filing outlines its capital structure, clinical pipeline, and strategic collaborations, highlighting its proprietary XpressCF platform and lead candidate, luvelta.

Sutro Biopharma, Inc. director Jon Marc Wigginton was granted stock options for 10,000 shares of common stock.

Sutro Biopharma director Daniel H. Petree acquired 10,000 stock options with an exercise price of $26.09, vesting over time with full vesting by June 5, 2027.

James P. Panek, a Director at Sutro Biopharma, Inc., acquired 10,000 stock options with an exercise price of $26.09.

Sutro Biopharma Director Joseph M. Lobacki acquired 10,000 stock options with an exercise price of $26.09, vesting over time with full vesting by June 5, 2027.

Sutro Biopharma director Jagpal Sukhi was granted 10,000 stock options with an exercise price of $26.09, vesting over time.

Heidi Hunter, a Director at Sutro Biopharma, Inc., acquired 10,000 stock options with an exercise price of $26.09.

Sutro Biopharma announces its 2026 Annual Meeting of Shareholders, scheduled for June 5th, to elect directors, ratify auditors, and vote on executive compensation.

Sutro Biopharma's upcoming annual meeting includes proposals for director elections, auditor ratification, executive compensation approval, and a potential reverse stock split.

Sutro Biopharma announces its 2025 Annual Meeting of Shareholders to be held virtually on June 6, 2025, including proposals for director elections, auditor ratification, executive compensation approval, and a potential reverse stock split.

Sutro Biopharma issued a supplement to its proxy statement to correct a typographical error regarding the deadline for stockholders to submit proposals for the 2025 annual meeting.

Sutro Biopharma announces its 2024 Annual Meeting of Stockholders to be held virtually on June 6, 2024, featuring proposals for director elections, auditor ratification, executive compensation, and ESPP amendment.

Sutro Biopharma's upcoming annual meeting on June 6, 2024, will address the election of directors, ratification of Ernst & Young LLP as the accounting firm, executive compensation, and an amendment to the Employee Stock Purchase Plan.

Kynam Capital Management, LP has filed a Schedule 13G reporting a 5.27% beneficial ownership stake in Sutro Biopharma, Inc.

Affinity Asset Advisors, LLC and Michael Cho have reported beneficial ownership of 1,069,519 shares, representing 6.5% of Sutro Biopharma, Inc.'s common stock as of March 31, 2026.

Point72 Asset Management and Steven A. Cohen have reported a 5.7% beneficial ownership stake in Sutro Biopharma, Inc. via a Schedule 13G filing.

Millennium Management LLC and Israel A. Englander have filed a Schedule 13G reporting a 1.3% beneficial ownership stake in Sutro Biopharma, Inc.

Perceptive Advisors LLC and Joseph Edelman have reported a 5.4% beneficial ownership stake in Sutro Biopharma, Inc. via a Schedule 13G filing.

A group of entities associated with Biotechnology Value Fund and Mark N. Lampert reported beneficial ownership of 7.6% of Sutro Biopharma, Inc.'s common stock.